| Galecto Reports Third Quarter 2024 Financial Results | 11/01 08:30 | globenewswire.com |
| Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler | 10/15 08:30 | globenewswire.com |
| Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines | 10/07 08:45 | globenewswire.com |
| Galecto Announces Reverse Stock Split | 08/28 09:00 | globenewswire.com |
| Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab | 05/01 16:01 | globenewswire.com |
| Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock? | 02/14 13:01 | zacks.com |
| New Strong Buy Stocks for February 14th | 02/14 06:50 | zacks.com |
| What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock | 01/09 18:02 | zacks.com |
| Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis | 12/21 16:05 | globenewswire.com |
| Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial | 10/23 08:00 | globenewswire.com |